Armistice Capital’s PDL BioPharma, Inc. PDLI Stock Holding History

Armistice Capital’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,800,000	Closed	-$4.73M	–	110
2018 Q3	$4.73M	Buy	+1,800,000	New	+$4.42M	0.28%	64
2017 Q2	–	Sell	-500,000	Closed	-$1.14M	–	70
2017 Q1	$1.14M	Buy	+500,000	New	+$1.11M	0.23%	46
2016 Q4	–	Sell	-2,632,000	Closed	-$8.82M	–	67
2016 Q3	$8.82M	Buy	+2,632,000	New	+$8.35M	2.83%	11

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Armistice Capital's PDLI Position: Q4 2018 in Review

Armistice Capital sold out of PDL BioPharma, Inc. (PDLI) in Q4 2018, closing a stake of 1,800,000 shares — an estimated $4.73M sold.

Armistice Capital first reported a position in PDLI in Q3 2016 and held it in 3 quarters. The position peaked at $8.82M in Q3 2016. 154 funds tracked by Wall St. Rank hold PDLI as of Q4 2018.

Armistice Capital reported no remaining PDL BioPharma, Inc. position as of Q4 2018 after selling out during the quarter.
Armistice Capital sold 1,800,000 PDL BioPharma, Inc. shares in Q4 2018, an estimated $4.73M.
Armistice Capital first reported a position in PDL BioPharma, Inc. in Q3 2016 and held it in 3 quarters.
Armistice Capital's PDL BioPharma, Inc. position peaked at $8.82M in Q3 2016.
154 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2018.

Based on Armistice Capital's 13F filing for Q4 2018, filed 14 Feb 2019.